Georgia Expands Medical Cannabis Access With Vaping Rights

Georgia patients with lupus and a range of other qualifying conditions gained new legal options on May 12, 2026, when Gov. Brian Kemp signed legislation overhauling the state’s medical cannabis program — authorizing vaping as a delivery method, replacing the program’s THC concentration cap with a dosage-based possession limit, and stripping gatekeeping requirements that had blocked earlier access for years.

The move brings Georgia’s program into closer alignment with the medical cannabis frameworks in place across most of the country, though recreational use remains illegal and Kemp was explicit that this change doesn’t signal a broader policy shift.

What the Law Does

The Putting Georgia’s Patients First Act, sponsored by Sen. Matt Brass, cleared both chambers of the General Assembly by wide margins — 38–14 in the Senate and 144–21 in the House. It makes several structural changes to a program that, since its 2015 launch, had operated under some of the tightest constraints of any state medical cannabis law.

On delivery methods, vaporization is now authorized for registered patients 21 and older — the first time the program has permitted any form of inhalation. Previously, patients were limited to oils, tinctures, capsules, lozenges, topicals, and transdermal patches. As MyCannabis has covered, those methods take longer to produce therapeutic effects than inhalation, a meaningful gap for patients managing acute symptoms. Smoking remains prohibited for all patients.

The THC framework is restructured in a way that matters more than the headline number. Georgia had imposed a 5 percent concentration cap on cannabis products — a potency limit on products themselves, which constrained what patients could access at dispensaries. The signed law drops that percentage ceiling entirely and replaces it with a possession limit: registered patients may hold products containing a cumulative total of up to 12,000 milligrams of THC. That’s a fundamental shift in regulatory logic. Instead of limiting how strong a product can be on the shelf, the law limits how much active THC a patient can carry at one time. The result is more flexibility for physicians and pharmacists to match products to patients.

Qualifying conditions expand as well. Lupus is added to an existing list that already includes cancer, Parkinson’s disease, multiple sclerosis, Alzheimer’s disease, ALS, autism spectrum disorder, PTSD, and intractable pain. The law also removes a gatekeeping requirement that had required many conditions to reach a severe or end-stage point before a patient could qualify — a threshold that blocked earlier intervention for patients whose conditions were progressing but hadn’t yet hit crisis level. The practical effect is that more patients, earlier in the course of their illness, can access the program.

The terminology shift is also complete: references to “low THC oil” — the framing that defined Georgia’s program since 2015 — are replaced with “medical cannabis” throughout state law, including in the patient registry.

What Stays — and What Else Changes

Recreational cannabis remains illegal in Georgia. Kemp made that clear in his signing statement, expressing reservations about adult-use legalization and arguing that a well-run medical program doesn’t need to lead there. For some patients, he said, the program delivers relief that would otherwise go untreated or be managed with opioids — that’s the basis on which he signed.

The law adds out-of-state reciprocity: registered patients from other states are now recognized in Georgia, addressing a practical problem for travelers and recently relocated patients. That recognition lapses once a person has been in the state for 45 days, at which point they would need to register under Georgia’s program directly.

A physician residency requirement takes effect as well. Treating physicians must maintain their principal medical practice in Georgia — a structural safeguard against out-of-state telehealth prescribers operating at the fringe of the patient-physician relationship.

The Georgia Access to Medical Cannabis Commission, which administers the state program, picks up a new public education mandate: it is now responsible for outreach to patients, healthcare providers, and law enforcement about the program’s scope and what patients are legally permitted to do. That’s a significant addition for a program that has operated in relative obscurity since 2015.

Catching Up With the Rest of the Country

Georgia carved out a distinctive — and limiting — position in 2015 by passing a medical cannabis access law while keeping the program narrower than virtually any other state. The “low THC oil” designation reflected that: it wasn’t branded as medical cannabis because, in practice, it barely functioned as one. The state’s restrictive approach has contributed to an environment where cannabis policy diverged sharply between the legal framework on paper and patients’ practical options.

The 2025 House study committee on medical cannabis and hemp policy was convened specifically to address that gap — examining what changes would modernize the program while remaining acceptable in a state where recreational legalization is not on the table. The bill Kemp signed incorporates the committee’s framework nearly in full.

What takes effect now is a meaningfully different program. Dispensaries gain a broader product menu. Patients gain inhalation access, a more flexible THC framework, and a shorter path to qualifying with progressive conditions. The commission gets the resources and mandate to explain all of it. Georgia’s medical cannabis infrastructure will need to build toward those new parameters — but the legal foundation is now in place.